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Abstract
For patients who are unresponsive to pharmacological treatments of glaucoma, an implantable glaucoma drainage
devices (GDD) are often used to manage the intraocular pressure. However, the microscale channel that removes
excess aqueous humor from the anterior chamber often gets obstructed due to biofouling, which necessitates
additional surgical intervention. Here we demonstrate the proof-of-concept for smart self-clearing GDD by integrating
magnetic microactuators inside the drainage tube of GDD. The magnetic microactuators can be controlled using
externally applied magnetic ﬁelds to mechanically clear biofouling-based obstruction, thereby eliminating the need for
surgical intervention. In this work, our prototype magnetic microactuators were fabricated using low-cost maskless
photolithography to expedite design iteration. The fabricated devices were evaluated for their static and dynamic
mechanical responses. Using transient numerical analysis, the ﬂuid–structure interaction of our microactuator inside a
microtube was characterized to better understand the amount of shear force generated by the device motion. Finally,
the anti-biofouling performance of our device was evaluated using ﬂuorescein isothiocyanate labeled bovine serum
albumin. The microactuators were effective in removing proteinaceous ﬁlm deposited on device surface as well as on
the inner surface of the microchannel, which supports our hypothesis that a smart self-clearing GDD may be possible
by integrating microfabricated magnetic actuators in chronically implanted microtubes.

Introduction
Glaucoma is a group of eye diseases that causes progressive damage to optic nerve. It is commonly known as
“the silent thief of sight” due to the lack of symptoms
during the early stages1. Because of this difﬁculty in early
diagnosis, glaucoma remains as one of the leading causes
of blindness and visual impairments in the world2. It
currently affects around 64.3 million people in the world
and this number is expected to double by 20403,4. In the
United States, there are more than 3 million patients with
glaucoma and it disproportionally affects African Americans and Hispanics5–9. Glaucoma is a major healthcare
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issue with the annual cost for treatment in the US that
exceeds $2.9 billion10.
Typically, glaucoma patients experience poor drainage
of aqueous humor (AH) through the natural outﬂow
pathways (i.e., trabecular meshwork and Schlemm’s
canal)11. The imbalance between the rate of production
and the outﬂow of AH from the eye causes an increased
intraocular pressure (IOP), which is a major risk factor
that leads to subsequent damage to optic nerve and the
loss of eyesight12,13. Unfortunately, there is no cure for
glaucoma. However, the progression of disease can signiﬁcantly be delayed using pharmaceutical and surgical
interventions that maintain the IOP in a safe range to
minimize optic nerve damage14. Glaucoma drugs are
typically designed to decrease the production of AH or to
increasing its outﬂow through trabecular meshwork or
uveoscleral pathway15–18. As with most pharmaceutical
interventions, however, these drugs have several undesirable side effects including bitter taste, headache,
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conjunctivitis, visual blurring, eyelid inﬂammation, and
eye pain19–21. Surgical treatments such as trabeculectomy
and laser trabeculoplasty can also be used to increase AH
outﬂow but these invasive procedures often lead to serious post-operative complications such as hypotony, cataract, and bleb-related infections22–25. Moreover, the
surgical ablation of trabecular meshwork often results in
coagulative necrotic tissue, which can cause difﬁculty in
chronic management of optimal AH outﬂow26.
For patients with refractory or inﬂammatory glaucoma
who are unresponsive to conventional pharmacological or
surgical procedures, glaucoma drainage device (GDD) are
often implanted. These devices offer several advantages
over conventional trabeculectomy including better IOP
control, ease of surgery, and minimum post-surgical
complications27–29. Traditional GDDs consists of a short
polymeric microscale tube that connects the anterior
chamber to a thin silicone plate for drainage of excess
AH30–32. While GDDs have been used to manage IOP for
glaucoma patients for the past 40 years, 15.1% of
implanted devices fail within 3 years and more than 29.8%
fail within 5 years post-implantation33,34. Clinical studies
have shown that up to 10% of glaucoma patients
require additional medications and surgical intervention
because of the tube blockage35. The hydrophobic polymer
materials from which GDDs are constructed (e.g., polypropylene,
polymethylmethacrylate,
and
polydimethylsiloxane) typically have high afﬁnity for
interstitial proteins such as ﬁbrinogen, immunoglobulin,
and albumin that adsorbs onto the device surface within
minutes after the implantation36–38. Once it forms, the
proteinaceous layer triggers the inﬂammatory response
that can lead to premature implantable device failure39.
Since GDDs generally have a drainage tube with an inner
diameter that ranges from 50 to 600 μm, the microscale
channel can easily be occluded by various biofouling
materials including vitreous, ﬁbrin, or blood clot40–43.
One promising approach that can remove adsorbed
biofouling material is to ablate occlusion using
neodymium-doped yttrium aluminum garnet (Nd:YAG)
laser. However, there are several potential risks associated
with laser treatments including focal cataracts, prolonged
elevation of the intraocular pressure, posterior capsule
rupture, retinal injury, and laser injury44–50. Tissue plasminogen activator (tPA), which is a serine protease
involved in the breakdown of ﬁbrin or blood clots, has
also been used to clear occluded glaucoma shunts51,52.
However, tPA may cause additional undesirable complications such as hyphema, active bleeding, and vitreous
hemorrhage53–55.
Establishing a method to non-invasively remove biofouling without causing side effects can signiﬁcantly
improve the reliability and functionality of many
chronically implanted devices. Here we report on the
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design, fabrication, and testing of anti-biofouling microtube integrated with an array of magnetic microactuators
as a part of a self-clearing GDD that can actively combat
against proteinaceous biofouling in situ without the need
for additional surgical or pharmaceutical interventions.
We believe our strategy to remove bioaccumulation ondemand using externally applied magnetic ﬁeld is a way
to signiﬁcantly improve the functional lifetime of
implantable devices that suffer from biofouling-related
performance degradation. By integrating thin-ﬁlm magnetic microactuators fabricated out of liquid crystal
polymer (LCP) using maskless lithography, here we
demonstrate a low-cost prototype of self-clearing GDD
drainage tube (Fig. 1). Using ﬂuorescent-tagged bovine
serum albumin, we show the protein-clearing capabilities
of these prototype GDD microtubes using time-varying
magnetic ﬁelds, which may eliminate the need for additional surgical or pharmaceutical interventions for glaucoma patients.

Results
Device fabrication and mechanical characterization

Figure 2a shows our microfabricated LCP-based device.
The needle-shape was chosen to accommodate the relatively small tube diameter. We can control the deﬂection
direction and amplitude of the microactuator by adjusting
the strength and the direction of the externally applied
magnetic ﬁeld (Fig. 2b). We assembled the microdevices
into a prototype GDD drainage tube using an anchor to
demonstrate protein-removal performance inside the
tube (Fig. 2c). Once manually placed into the microtube,
we heated the tube and applied tensile stress at both
ends to decrease the diameter of the microtube and ﬁx
the microactuators in position, which prevented any
shifting of devices during actuation in a continuous
ﬂuid ﬂow.
To characterize the actuation capabilities of our magnetic microactuators, we evaluated the static and dynamic
mechanical responses. A magnetic moment of the soft
ferromagnetic element is generated when the magnetic
microactuator is placed in a static magnetic ﬁeld. The
microactuators can deﬂect out of plane when the direction of the applied magnetic ﬁeld is normal to the magnetization direction of the ferromagnetic element
(Fig. 2b). The deﬂection angle of magnetic microactuator
can be described in the ref. 56


~ ´H
~
Vm M
ð1Þ
ϕ¼
kbeam
with the angular deﬂection ϕ, magnet volume Vm, mag~ applied magnetic ﬁeld H,
~ and the ﬂexure
netization M,
stiffness kbeam. The beam geometry and the material
property affect the mechanical stiffness of the ﬂexure with
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with the elastic modulus Ec, beam width w, beam thickness t, and beam length l57,58.
As shown in Fig. 3a, the measured deﬂection angle
corresponded closely with the theoretical values. We
varied the frequency and amplitude of the externallyapplied, time-varying magnetic ﬁelds using a custom
electromagnet to obtain the frequency response (10–200
Hz) of our microactuators (Fig. 3b). As expected, the
amplitude of deﬂection increased as a function of applied
magnetic ﬁeld strength. Furthermore, we determined that
the actuation frequency of 20 Hz to be the primary
resonance, which can be used to generate the highest
dynamic deﬂection amplitude. The increase in dynamic
deﬂection amplitude may be attributable to the increase in
mean ﬂuid velocity around the microactuator, which leads
to an increase in the wall shear stress on the microactuator and the tube59,60. Therefore, we used a ﬁxed

actuation frequency (20 Hz) with the highest actuation
amplitude (64°) for all experiments and simulation.
To verify these Ti-coated LCP based microactuator is
robust enough to withstand a large number of actuation
cycles in physiological condition, we examined the changes
in the dynamic responses of these microdevices in 37 °C
phosphate buffered saline (PBS, ThermoFisher Scientiﬁc,
Waltham, MA, USA). After 10.9 million actuation cycles,
we saw no visible damage to the LCP-based microactuators
and no change in the resonant frequency of tested devices
(n = 4, Supplementary Fig. 1). If we assume a 5-min weekly
actuation, this equates to up to 35 years of lifetime, which
suggests adequate robustness for our LCP-based microactuators against fatigue related failure.
Fluid–structure interaction

We evaluated the shear stress distribution generated by
the microactuation motion using ﬁnite element modeling.
The simulation results showed that the maximum shear
stress is generated near the perimeter of the actuator
(Fig. 4a). When the device is integrated into the microtube, the actuation leads to a larger shear stress as the
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Fig. 2 Images of fabricated microactuators and self-clearing GDD. a Digital photograph of the fabricated magnetic microactuators. Scale bar =
200 μm b The deﬂected microactuator with different directional magnetic ﬂux density with 13.7 mT. Scale bar = 200 μm. c Digital photographs of the
integrated microactuators in the lumen of a prototype GDD microtube. Scale bar = 500 μm

microactuator approaches the tube wall (Fig. 4c). During
the actuation, the maximum shear stress of ~8 and ~10
dyn/cm2 are generated periodically on the surface of the
actuator and the tube, respectively (Fig. 4b, d).

τ m ¼ 0:16

BSA-FITC adsorption and desorption

To maximize the ﬂuorescence intensity, we incubated
Ti-coated LCP samples in various concentrations of BSAFITC (1–8 mg/ml) for 2 h. The ﬂuorescence intensity of
absorbed BSA-FITC plateaued around 5 mg/ml (Fig. 5a),
therefore, all subsequent BSA-FITC evaluations used this
concentration. The jet impingement technique is widely
used to analyze the shear stress required to remove cells
by corresponding the size of a lesion created by a perpendicular jet of ﬂuid to a well-characterized shear stress
proﬁle61,62. To quantify the adhesion strength of BSAFITC on Ti-coated LCP surface, we used the theoretical
description of the wall shear stress under the impinging
jet proposed by Phares et al.63. For this analysis, we
assumed that the AH is incompressible Newtonian ﬂuid
in a steady and laminar ﬂow. In the theoretical description
of the wall shear stress in normally impinging jet with jet
height H, the wall shear stress τ at a radial distance r can
be described by
τ
1  e114λ
¼ 0:18
λ
τm

2

with the maximum shear stress τm and nondimensionalized jet height (λ = r/H). The maximum
shear stress τm is given by

!
 0:943λe114λ

2

ð3Þ

ρu2o
ðH=DÞ2

ð4Þ

with the ﬂuid density ρ, the average ﬂow velocity at the
nozzle exit uo, and diameter for the nozzle D. The critical
shear stress (τc) required to remove the adsorbed BSAFITC can then be calculated by measuring the radius of
lesion (Fig. 5b).
In the jet impingement test, the ﬂuid jet was delivered at
a ﬂow rate of 1.18 ml/min for 5 s, which corresponds to
Reynolds number of 100 in laminar ﬂow range to be used
for Eqs. (3) and (4). The ﬂuid jet created τm ~ 30 dyn/cm2
which is in line with published shear stress value required
to rupture protein-ligand interaction64. Figure 5b shows
an image of BSA-FITC lesion created by jet impingement
and a plot of non-dimensional wall shear stress as a
function of non-dimensional lesion size for jet radius
Rjet = 125 μm. With an average lesion radius of 284 μm
(n = 4), the estimated shear stress required to remove
BSA-FITC (τc) was 10.2 dyn/cm2. The numerical analysis
results (Fig. 4) showed that our magnetic microactuators
can generate up to 10 dyn/cm2. Taken together with the
results from our jet impingement study, we expected to
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show a robust protein removal using our prototype GDD
drainage tube.
Protein biofouling removal in GDD

The main function of our magnetic microactuators is to
remove the protein adsorbed on the device surface and
the inner wall of GDD microtube to prevent the initiation
of inﬂammatory cascade. As such, we quantiﬁed the
decrease in ﬂuorescence intensity due to device actuation
on device surface and the inner wall of the microtube as
simulated in Fig. 4. To study anti-biofouling capability of
the actuator itself, we actuated BSA-FITC coated devices
with different actuation durations at 20 Hz. The maximum actuation duration was set to 5 min based on prior
literature65,66 and for practical consideration assuming
that a shorter actuation protocol would be less burdensome on clinicians and patients. The minimum actuation
duration was set to be 30 s, which is 10% of the maximum
actuation duration.
Figure 6 demonstrates BSA-FITC removal due to
actuation of magnetic microdevices. We compared the

decreased ﬂuorescence intensity values using one-way
analysis of variance (ANOVA) with Tukey’s HSD posthoc pairwise analysis. The results showed that BSA-FITC
coated on microactuators (n = 3) was signiﬁcantly
reduced compared to non-actuated control regardless of
deﬂection amplitude or actuation duration (p < 0.01).
Without actuation, the ﬂuorescence intensity decreased
by approximately 10–20% depending on treatment duration. However, the difference in ﬂuorescent intensity
between the small (8°) and large (64°) deﬂection magnitudes was not statistically signiﬁcant. The impact of
actuation duration was also statistically signiﬁcant. When
actuated for 30 s, BSA-FITC amount reduced by 42%.
whereas up to 85% protein clearance can be seen on
device when actuated for 5 min. Thus, in subsequent
evaluations to determine the impact of actuation on
removing protein adsorbed on the microtube inner wall,
we actuated all samples for 5 min to maximize protein
clearance.
To demonstrate the in situ anti-biofouling performance
of our smart GDD, we coated the inner lumen of
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Fig. 4 Numerical analysis of shear stress distribution. a Shear stress distribution generated on the surface of the actuators. b Maximum shear
stress on the actuator surface as a function of time. c Shear stress distribution generated on the tube. d Maximum shear stress from the internal
surface of the microtube as a function of time

300-μm-diameter microtube integrated with our magnetic
microactuator using BSA-FITC (Fig. 2c). Figure 7a highlights the difference in ﬂuorescence intensity between
actuated versus non-actuated GDD prototype. Without
actuation, we saw virtually no difference in ﬂuorescence
intensity. Following actuation, however, we saw a signiﬁcant decrease in ﬂuorescence intensity in areas surrounding the microdevice. The pattern of cleared area
closely resembles the shear stress distribution predicted
by our numerical analysis (Fig. 4). We then quantiﬁed the
amount of ﬂuorescence intensity decrease from the end of
the beams to the actuator tip and compared the results
using a two-sample t-test. The results show that the
microactuation can remove signiﬁcant amount of adsorbed BSA from the tube wall compared to the nonactuated control (p < 0.01, Fig. 7b). However, the decrease
in ﬂuorescence intensity (<40%) in microtube was much
smaller than the 85% decrease we saw from the device
surface following a 5 min actuation (Fig. 6b).

Discussion
Here we demonstrated that the LCP-based microactuators can easily be fabricated at low-cost using our
maskless photolithography. LCP is widely used polymer in

biomedical applications due to their near hermetic
properties, biocompatibility and superior chemical resistance67–70. By using commercially available low-cost LCP
sheets as the substrate in combination of highly scalable
microfabrication processes such as maskless photolithography, oxygen etching, electroplating, and polymer
coating, it is possible to manufacture these LCP-based
devices at extremely low costs. Moreover, the simple
integration process that we employed to immobilize
microdevices inside a small drainage tube may be used to
create other smart MEMS-enabled catheter-based
devices.
Both the static and the dynamic responses of these
microfabricated LCP-based actuators corresponded well
with the theoretical values, which suggests a good control
of our fabrication process. The in vitro evaluation using
BSA-FITC showed that, as expected, the actuation from
our device can effectively reduce proteinaceous biofouling
on the actuator surface and the inner wall of the microtube. The results from the in vitro experiments demonstrated a good agreement with our results from the
numerical analysis that predicted the pattern of bioﬁlm
clearance by quantifying the shear stress distribution and
the jet impingement study that quantiﬁed the adhesion
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strength of the BSA-FITC. This approach to quantify the
adhesion properties of speciﬁc bioﬁlm and to model the
shear stress proﬁle of a device actuation may be used in
future iterations to design novel microactuator arrays that
are tailored for bespoke implantable application against
speciﬁc biofouling materials.
To conﬁrm that the biofouling removal process does
occur via mechanical shear generated by the microactuation and not by the heat generated from the
microactuation, we also measured the amount of heat
generated during actuation (Supplementary Fig. 2). When
we actuated our microdevices (n = 4) for 5 min at 20 Hz
using 40 mT in room temperature PBS, no temperature
increase was seen in thermal camera images (FLIR

Decreased fluorescence intensity (%)
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20

0
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8 Deg

64 Deg

Fig. 6 Impact of actuation amplitude and duration. a Fluorescence
intensities (a. u.) of BSA-FITC coated microactuators before and after
actuation using different deﬂection amplitudes and actuation
duration at 20 Hz. Signiﬁcant protein removal can be seen for both
small and large amplitude actuation. The difference map shows a
more signiﬁcant protein removal with longer actuation duration. Scale
bar = 200 μm. b Comparison of decreased ﬂuorescence intensity
(n = 3 for each actuation condition). * and # indicates statistical
signiﬁcance against corresponding control (p < 0. 01)

A325sc, FLIR, Wilsonville, OR, USA). It is important to
ensure that no thermal effect occurs due to microactuation since excessive heat may lead to unintended damage
to the surrounding tissue.
The potential implication of utilizing active mechanism
for combating biofouling is enormous since many
chronically implantable devices including biosensors,
neural interface electrodes, and drug delivery and drainage devices suffer from signiﬁcant performance
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degradation due to biofouling39,71. Although there is a
number of proposed mechanisms for actively addressing
biofouling using electrical and mechanical transducers65,
the magnetically-powered actuators have several key
advantages. First, the magnetic device can be activated
in situ wirelessly via externally applied magnetic ﬁeld with
low power requirements (Supplementary Fig. 3) without
the need for any invasive procedure. Second, the magnetic
microactuators can be tailored to deliver large disruptive
forces to remove multi-scale biofouling materials including protein, bacteria, and cells. Third, the lack of integrated circuit and internal power source can facilitate the
integration and packaging of these type of devices into
existing medical devices, which can accelerate clinical
adoption. Finally, as mentioned, the simple design is
compatible with many scalable microfabrication technologies that can signiﬁcantly reduce the cost of
manufacturing.
Despite these key beneﬁts, there are several remaining
questions to be answered. First, the amount of protein

removed from the microtube wall was much lower than
that from the actuator surface despite our numerical
analysis demonstrating a higher maximum shear stress on
the wall. This may be due to the fact that each microscope
image was focused on microactuator surface, which is
located at the center of the microtube. As can be seen
from Fig. 4 and the Supplementary Video, the magnitude
of shear stress distribution around the mid-plane of
microtube is much lower than the top and bottom of the
microtube. It may be interesting to characterize protein
distribution using a confocal microscope in the future to
verify this hypothesis. If not, it is possible to leverage our
predictive modeling to redesign microactuators that can
provide a greater average shear stress to ensure a more
efﬁcient protein-removal. Secondly, additional experiments are needed to determine optimum actuation duty
cycle that will ensure a protein-free GDD microtube.
Although the microactuators were able to demonstrate
good protein reduction in just 5 min, it may be possible to
reduce this actuation duration further by performing a
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systematic evaluation. Thirdly, although it is possible to
integrate many microactuators into a long microtube
(Supplementary Fig. 4), the manual assembly process can
be further streamlined if 1D arrays of microactuators are
fabricated to better control the device spacing. Finally,
additional in vitro and in vivo work is necessary to
ascertain whether periodically removing bioﬁlm using our
self-clearing implants will actually prolong the device
lifetime and improve patient outcome. A critical question
to address is to determine what happens with the displaced biofouling material. A detailed histopathological
evaluations using animal models must be performed to
ensure that the displaced biomaterial will not cause
undesirable downstream effects.

Materials and methods
Device fabrication

We fabricated the microactuators from copper-(Cu)cladded LCP using a custom maskless photolithography
setup previously described72. We used a computer connected to a conventional home theater projector with a
digital micromirror device (HD142X, Optoma, Fremont,
CA, USA) to project and expose a desired pattern72–75.
The projector was vertically ﬁxed on a stereo-microscope
(SM-4B, Amscope, Irvine, CA, USA) using a custom
machined bracket. To improve the resolution and reduce
the size of the image, we optimized the alignment between
the lens of the microscope, the sample stage, and the
projector. We used Microsoft PowerPoint to design and
project various mask patterns. We adjusted the exposure
intensity by modifying pattern color in the software. Figure 1c shows the overall process ﬂow for the device
fabrication.
The commercially available LCP sheet (Ultralam 3850,
Rogers corporation, Chandler, AZ, USA) has a thickness of
25 μm. To improve compliance of the cantilevers, we
reduced the LCP thickness to 8 μm using a reactive ion
etcher (RIE, PlasmaPro80, Oxford Instruments plc,
Abingdon, Oxfordshire, United Kingdom) after removing
Cu from one side using a wet Cu etchant (CE-100,
Transene, Danvers, MA, USA). We then mounted the
8-μm-thick single clad LCP sheet onto a carrier wafer
using a positive photoresist (PR) (AZ9260, Microchem,
Westborough, MA, USA) with the Cu on top. We spin
coated AZ9260 onto the Cu layer and exposed the cantilevers designs using our custom maskless photolithography setup. After etching the Cu layer using a wet
Cu etchant (CE-100, Transene, Danvers, MA, USA), we
removed PR using acetone. Next, we deﬁned the Ni
magnet electroplating mold on spin-coated AZ9260 using
the same maskless photolithography procedure. We electroplated Ni to achieve a ﬁnal thickness of 20 μm. After
removing the PR, we etched the cantilever pattern on bare
LCP layer using an RIE and removed the remaining Cu
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layer using a chemical etchant (BTP, Transene, Danvers,
MA, USA). Finally, we coated the device with 100 nm thick
titanium (Ti) using a sputterer (Magnetron sputtering
systems, PVD Products, Inc., Wilmington, MA, USA) on
both sides to improve biocompatibility.
Mechanical characterization

We measured the magnitudes of angular deﬂections for
a range of applied magnetic ﬂux density up to 40.9 mT.
We used a bespoke iron-core electromagnet to generate
the magnetic ﬁeld. We quantiﬁed the strength of magnetic
ﬁeld using a commercial gaussmeter (Model 8010, Paciﬁc
Scientiﬁc OECO, Milwaukie, OR, USA). We then placed
the device on top of the electromagnet and applied the
magnetic ﬁeld of varying amplitude and frequency. We
imaged the deﬂected actuators using a digital microscope
KH8700, Hirox, Hackensack, NJ, USA) and calculated the
deﬂection angles from the images using imageJ software
(version 1.50i). To better characterize the motion of the
devices in liquid, we also characterized the dynamic
responses of the magnetic microactuators in deionized
water using a custom laser deﬂecting setup. Using a
mirror, we placed a laser beam onto the metallic surface
of the device, which then reﬂected the laser beam onto a
position sensitive diode (PSD) sensor. We recorded the
two-dimensional position data from the PSD using a
custom data acquisition system (LabView 2014, Austin,
TX, USA).
Fatigue evaluation

As a baseline, we photographed and measured the
dynamic responses of each test sample (n = 4). We
immobilized each microactuator on glass slide using
polyimide tape for the fatigue evaluation. We then placed
the glass slide ﬁxture in a beaker ﬁlled with PBS at 37 °C.
We actuated the device for 6 days to achieve 10.9 million
cycles at 12 mT and 20 Hz sinusoidal signal. Following the
continuous actuation, the microactuators were removed
from the beaker, photographed, and analyzed for postactuation dynamic response.
Fluid–structure interaction

To determine the shear stress generated by the actuation, we used a ﬁnite volume method to simulate shear
stress on the surface of microactuator and the lumen of
the microtube by numerically solving Navier–Stokes
equations. We discretized the computational domain
using a uniform, staggered, cartesian grid. We used Euler
explicit method for time discretization and spatial derivatives in convective and computed diffusive terms using
the quadratic upstream interpolation for convective
kinematics and central difference schemes, respectively76.
Furthermore, we coupled the pressure and velocity using
a projection method77. We implemented a distributed
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Lagrange multiplier method to simulate the motion of
microactuator in a viscous ﬂuid, which allowed us to
accurately capture the hydrodynamic interaction between
the microactuator and a surrounding ﬂuid and evaluate
the shear stress acting on the surface78,79.
Protein-based biofouling adhesion

We tested the anti-biofouling performance of our
magnetic microactuators using ﬂuorescent-tagged bovine
serum proteins (BSA-FITC, ThermoFisher Scientiﬁc,
Waltham, MA, USA), which is readily coated onto the
implant surface via non-speciﬁc binding and subsequently
initiates the inﬂammatory response in vivo80. We incubated the devices and samples for jet impingement test in
the BSA-FITC solution of various concentrations
(1–8 mg/ml) in PBS (n = 5, each) for 2 h and rinsed with
deionized water. We captured the images of protein
coated samples using a ﬂuorescence microscope (Axio
Observer Z1, Carl Zeiss Microscopy, LLC) and a ﬁlter set
17 (excitation, BP 485/20, and emission BP 515-565, Carl
Zeiss Microscopy, LLC), and quantiﬁed the ﬂuorescence
intensity using imageJ. We normalized each image using
the imageJ against bare non-coated sample.
We quantiﬁed the magnitude of shear stress required to
remove the absorbed protein on Ti-coated surface using a
jet impingement experiment. We vertically placed the tip
of a 15-ml syringe with the needle having an inner diameter of 250 μm (7018333, Nordson EFD, East Providence, RI, USA) 1 mm over BSA-FITC coated substrate
and delivered the jet ﬂow using a syringe pump (NE-300,
New Era Pump Systems, Inc., Farmingdale, NY, USA). We
created a total of four lesions. Using the same ﬂuorescence microscope describe above, we imaged of each
lesion and measured the diameter of each using imageJ.
We subtracted the background ﬂuorescence from bare
substrate to normalize ﬂuorescence intensity,
Protein biofouling removal in GDD

We investigated the impact of deﬂection amplitude (8° vs.
64°) and actuation duration (30 s vs. 5 min) of our magnetic
microactuators by quantifying the amount of BSA-FITC (n
= 3, each). We placed each sample in deionized water in a
custom testing chamber to block the ambient light during
actuation. We captured the ﬂuorescence images of proteincoated devices before and after the actuation and quantiﬁed the difference in ﬂuorescence intensity using imageJ.
We normalized the background ﬂuorescence by subtracting ﬂuorescencefrom a bare actuator surface. To demonstrate the anti-biofouling capability of magnetic
microactuators inside a polytetraﬂuoroethylene microtube,
we coated the lumen of assembled GDD drainage tube by
ﬂowing BSA-FITC at 2.7 μl/min, which is the average ﬂow
rate of AH in human eyes. We then actuated the microdevices at 20 Hz for 5 min to remove the adsorbed protein
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layer (n = 3). Finally, we quantiﬁed the decrease in ﬂuorescence level due to actuation and compared with the nonactuated controls.
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